Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $481.0 million Upfront Cash: $44.0 million
Deal Type: Collaboration December 20, 2020
Details:
GSK licenses global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design platform. The licensed products includes an advanced lead preclinical drug as well as multiple differentiated back-up compounds.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMU-856
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Immunic Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
Details:
The option and license agreement gives Immunic the exclusive rights to commercialization of IMU-856 in all countries.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
